Pancreatic AdenocarcinomaStage 0 Pancreatic Cancer American Joint Committee on Cancer v8Stage I Pancreatic Cancer American Joint Committee on Cancer v8+2 more

PrincipalinvestigatorStart date: 2021-05-27

NCT04005690Early Phase 1Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal Adenocarcinoma+5 more

PrincipalinvestigatorStart date: 2019-08-01

NCT06398587Phase 2Withdrawn

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8+3 more

Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Stage II Pancreatic Cancer AJCC v84 Stage III Pancreatic Cancer AJCC v84 Stage IV Pancreatic Cancer AJCC v84 Locally Advanced Pancreatic Ductal Adenocarcinoma3 Metastatic Pancreatic Ductal Adenocarcinoma3 Borderline Resectable Pancreatic Ductal Adenocarcinoma1 Locally Advanced Pancreatic Adenocarcinoma1 Metastatic Pancreatic Adenocarcinoma1

Affiliations

OHSU Knight Cancer Institute

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Vincent Chung

City of Hope Medical Center

9 trials

Shared therapeutic areas:

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal Adenocarcinoma+6 more

Similarity Score15%

Flemming Forsberg, phD

Thomas Jefferson University

9 trials

Shared therapeutic areas:

Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8+5 more

Similarity Score13%

Christos Fountzilas

Roswell Park Cancer Institute

6 trials

Shared therapeutic areas:

Metastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8Borderline Resectable Pancreatic Ductal Adenocarcinoma+4 more

Similarity Score12%

Patricia M LoRusso

Yale University Cancer Center LAO

6 trials

Shared therapeutic areas:

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+2 more

Similarity Score8%

Siqing fu

M.D. Anderson Cancer Center

6 trials

Shared therapeutic areas:

Stage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8+2 more

Similarity Score8%

A P Chen

National Cancer Institute LAO

8 trials

Shared therapeutic areas:

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8

Similarity Score5%

Eileen O'Reilly, MD

Memorial Sloan Kettering Cancer Center

5 trials

Shared therapeutic areas:

Metastatic Pancreatic AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaPancreatic Adenocarcinoma

Similarity Score5%

Erkut Borazanci, MD

HonorHealth Research Institute

7 trials

Shared therapeutic areas:

Pancreatic AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma

Similarity Score3%

Guopei Luo, MD

Fudan University

6 trials

Shared therapeutic areas:

Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma

Similarity Score3%

Kerri Winters-Stone

OHSU Knight Cancer Institute

8 trials

Shared therapeutic areas:

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8

Worked with same sponsors:

OHSU Knight Cancer InstituteOregon Health and Science University

Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT07089940Early Phase 1PrincipalInvestigator

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8+2 more

Recruiting

NCT05034627Phase 1PrincipalInvestigator

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC v8+4 more

Completed

NCT04539808Phase 2PrincipalInvestigator

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Pancreatic AdenocarcinomaStage 0 Pancreatic Cancer American Joint Committee on Cancer v8Stage I Pancreatic Cancer American Joint Committee on Cancer v8+2 more

Active Not Recruiting

NCT04005690Early Phase 1PrincipalInvestigator

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal Adenocarcinoma+5 more

Recruiting

NCT06398587Phase 2PrincipalInvestigator

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8+3 more

Withdrawn

All 5 trials loaded